Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
NCT06572085

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients

Led by Tang Ziren · Updated on 2025-04-11

350

Participants Needed

1

Research Sites

312 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.

CONDITIONS

Official Title

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-80 years old
  • Glasgow Coma Scale (GCS) score 8 or less upon admission
  • Return of Spontaneous Circulation (ROSC) lasting 30 minutes or more
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Cardiac arrest caused by irreversible reasons such as trauma or poisoning
  • Cardiac arrest due to end-stage diseases like advanced cancer
  • Persistent cardiogenic shock not improving despite treatments (systolic blood pressure below 90 mmHg)
  • Pre-existing cerebrovascular disease or confirmed intracranial hemorrhage after admission
  • Pre-existing Cerebral Performance Category (CPC) scores of 3 to 5 before cardiac arrest
  • Prior use of butylphthalide (NBP) or medications containing NBP before cardiac arrest
  • Severe liver or kidney dysfunction before cardiac arrest (defined by lab tests)
  • Bradycardia or sick sinus syndrome after return of spontaneous circulation
  • History of drug or food allergies or allergies to study medication components
  • Refusal of advanced life support treatments by patient or legal representative
  • Severe bleeding tendency upon admission
  • Body temperature below 30°C upon admission
  • Pregnant or breastfeeding women, or women of reproductive age with elevated serum human Chorionic Gonadotropin (hCG)
  • Other conditions the principal investigator deems unsuitable for the trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Chao-Yang Hospital

Beijing, Beijing Municipality, China, 100020

Actively Recruiting

Loading map...

Research Team

Z

Ziren Tang, Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients | DecenTrialz